Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cisplatin + Gemcitabine + Pembrolizumab |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 7 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
| Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 14 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
| Pembrolizumab | Keytruda | MK-3475 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, PMBL, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous SCC, MSI-H or dMMR or TMB high advanced solid tumors, NSCLC and CD274 (PD-L1)-positive NSCLC, esophageal SCC, cervical cancer, and TNBC, in combination with platnum-based chemo in NSCLC, with pemetrexed and platinum in pleural mesothelioma and non-sNSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in sNSCLC, with axitinib or lenvatinib in RCC, with lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, in combination with platinum and fluoropyrimidine-based chemo for esophageal or gastroesophageal carcinoma, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemo for CD274 (PD-L1)-positive, HER2-positive gastric or GEJ adenocarcinoma, in combination with fluoropyrimidine- and platinum-containing chemo for HER2-negative gastric or GEJ adenocarcinoma, in combination with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-positive (CPS>=1) cervical cancer, in combination with gemcitabine and cisplatin for biliary tract cancer, in combination with chemoradiation for cervical cancer, and in combination with carboplatin and paclitaxel for endometrial carcinoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03425643 | Phase III | Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine | Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) | Active, not recruiting | USA | ROU | POL | LVA | LTU | ITA | IRL | GBR | FRA | EST | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 8 |
| NCT02690558 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy | Active, not recruiting | USA | 0 |
| NCT04267848 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial | Recruiting | USA | 1 |
| NCT05967182 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma | Recruiting | USA | 0 |
| NCT06312137 | Phase III | Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab + SKB264 | A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | Recruiting | USA | ROU | POL | NOR | NLD | ISR | GRC | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
| NCT04003636 | Phase III | Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966) | Active, not recruiting | USA | TUR | NZL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 8 |
| NCT06282575 | Phase III | Cisplatin + Durvalumab + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab Cisplatin + Durvalumab + Gemcitabine + ZW25 Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab + ZW25 Cisplatin + Gemcitabine + ZW25 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | Recruiting | USA | ITA | ISR | ESP | CAN | ARG | 8 |
| NCT02608684 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer | Completed | USA | 0 |
| NCT03924856 | Phase III | Cisplatin + Gemcitabine + Pembrolizumab Cisplatin + Gemcitabine | Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) (KEYNOTE-866) | Active, not recruiting | USA | TUR | SWE | POL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 6 |
| NCT06001658 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers | Recruiting | USA | 0 |
| NCT03260712 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | Pembrolizumab in Biliary Tract Cancer | Completed | GBR | ESP | DEU | 0 |
CKB BOOST